Cochrane Review Group
Childhood Cancer
15 systematic reviews in Childhood Cancer ask 165 questions. 30.3% have no studies to answer them, 7.9% rest on very low certainty evidence and 12.7% reach moderate or high certainty.
Reviews
15
Questions
165
current versions
No studies
30.3%
Moderate or high
12.7%
No studies 50 · 30.3%Ungraded 12 · 7.3%Very low 13 · 7.9%Low 69 · 41.8%Moderate 21 · 12.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV) Thromboembolism ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Secondary malignant neoplasms · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Clinical heart failure and subclinical myocardial dysfunction combined Defined as clinical heart failure (no definition provided) or subclinical myocardial dysfunction defined as decreased LVFS; however, it was stated that toxicity was graded acco... · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | 1 study · 537 participants | Very low |
Dexrazoxane vs no cardioprotective intervention Progression‐free survival · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Tumour response rate Defined as number of complete remissions (no definition of complete remission provided). Best‐case analysis · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | RR 1.01 [0.95, 1.07] | 1 study · 206 participants | Very low |
Dexrazoxane vs no cardioprotective intervention Quality of life · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Quality of life · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
Reviews 15
PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis
CochraneSoF table
21 questions
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
CochraneSoF table
6 questions
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
CochraneSoF table
6 questions
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
CochraneSoF table
20 questions
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
CochraneSoF table
5 questions
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
CochraneSoF table
7 questions
Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
CochraneSoF table
19 questions
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
CochraneSoF table
7 questions
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
CochraneSoF table
14 questions
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
CochraneSoF table
7 questions
Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropenia
CochraneSoF table
15 questions
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
CochraneSoF table
10 questions
Intracystic bleomycin for cystic craniopharyngiomas in children
CochraneSoF table
7 questions
Radiotherapy for diffuse brainstem glioma in children and young adults
CochraneSoF table
14 questions
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
CochraneSoF table
7 questions